Riverbridge Partners LLC Sells 54,889 Shares of Repligen Corporation $RGEN

Riverbridge Partners LLC lowered its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 17.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 258,476 shares of the biotechnology company’s stock after selling 54,889 shares during the period. Riverbridge Partners LLC owned about 0.46% of Repligen worth $30,454,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. United Capital Financial Advisors LLC bought a new position in Repligen in the third quarter valued at about $368,387,000. Opti Capital Management LP bought a new position in shares of Repligen in the fourth quarter worth about $2,399,209,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $199,176,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares in the last quarter. Finally, RTW Investments LP bought a new stake in shares of Repligen during the 4th quarter valued at approximately $174,347,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. HC Wainwright boosted their target price on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, May 7th. Finally, Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $164.64.

Repligen Stock Down 0.2%

Shares of NASDAQ RGEN opened at $126.37 on Wednesday. The company has a 50 day simple moving average of $121.94 and a 200 day simple moving average of $135.79. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77. The firm has a market cap of $7.13 billion, a PE ratio of 140.41, a price-to-earnings-growth ratio of 2.44 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, research analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.